CASGEVY generated $76 million in Q2 revenue, up 151% year-over-year and 78% versus the prior quarter. The surge expands the company's cash flow outlook and justifies its $2.36 billion balance sheet, improving investor confidence overall significantly despite a $-1.28 EPS miss.
Key Highlights
- EPS $-1.28 missed consensus of $-1.25, reflecting broader biotech earnings pressure
- Cash and marketable securities rose to $2,364.4 million, driven by $585.4 million convertible note proceeds
- R&D expenses fell to $67.2 million, while collaboration costs eased to $40.3 million
CRISPR Therapeutics AG (NASDAQ: CRSP) posted second‑quarter revenue of $76 million for its CASGEVY therapy, a 151% jump year‑over‑year and 78% rise sequentially. Earnings came in at $-1.28 per share, trailing the $-1.25 consensus. Cash and marketable securities climbed to $2,364.4 million, underscoring a strengthened balance sheet.
The data point to a company that is translating clinical milestones into commercial momentum while managing a modest earnings shortfall.
CASGEVY Revenue Leap
The gene‑edited cell therapy drove $76 million of revenue, marking a 151% increase from the same quarter last year and a 78% rise from the previous quarter. That growth stemmed from FDA approval for children as young as two, expanding the addressable patient pool by roughly 5,500 individuals. The therapy now reaches 39 countries, reinforcing global market penetration.
Compared with peers, MLTX rose 2.6% while ADCT held steady, highlighting CRISPR’s relative outperformance. The surge adds meaningful top‑line momentum, yet it also raises expectations for future sales ramps as reimbursement agreements unfold.
Balance Sheet Strengthened
Cash and marketable securities totaled $2,364.4 million at quarter‑end, up from $1,975.8 million at year‑end. The increase reflects $585.4 million raised from convertible senior notes issued in March, offset partially by operating expenses. A solid cash position provides runway for ongoing Phase 1 trials and upcoming regulatory submissions.
With a market capitalisation of $4.8 billion, the liquidity buffer translates to roughly 48 days of cash at current burn rates. Investors benefit from the reduced financing risk, especially as the company pursues broader reimbursement and commercial scaling.
Earnings Miss and Cost Discipline
Adjusted earnings of $-1.28 per share fell short of the $-1.25 estimate, a variance that mirrors broader biotech earnings pressure. Nonetheless, the company trimmed research and development spend to $67.2 million, down from $69.9 million a year earlier, and lowered collaboration expenses to $40.3 million from $45.2 million. General and administrative costs also eased to $17.6 million versus $18.9 million.
These cost curbs help offset the earnings gap while preserving momentum in the pipeline. The disciplined expense profile suggests management can sustain growth without sacrificing financial health.
Upcoming ESC Congress Catalyst
The European Society of Cardiology Congress on August 28 will host a late‑breaking abstract on CTX310 durability, offering a direct window into the company’s cardiovascular pipeline. The presentation follows a Phase 1b trial for severe hypertriglyceridemia that remains active in the second half of the year. Market participants will watch the data for signs of broader applicability of the LNP delivery platform.
The upcoming disclosure presents a clear near‑term catalyst for investors.
Peers Moving on This News
- MoonLake Immunotherapeutics (MLTX) up 2.6%
- ADC Therapeutics SA (ADCT) little changed
Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...